Roche has entered into an agreement with Evotec to fund the Phase II clinical development of a selective N-methyl-D-aspartate (NMDA) receptor antagonist, EVT 101, for patients with treatment ...

In a study published in Cell, a research team led by Zhu Shujia from the Center for Excellence in Brain Science and ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Now ketamine, a glutamatergic NMDA receptor antagonist, may provide a mechanism that could link these pathways. Figure 1: A schematic of how ketamine may lead to an overall excitation in the cortex.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

A research team led by Shujia Zhu from the Chinese Academy of Sciences’ (CAS) Center for Excellence in Brain Science and Intelligence Technology and Yang Li from the Shanghai Institute of Materia ...

It is the first and only oral NMDA receptor antagonist to be approved for this use, and the first oral therapy with a new mechanism of action in around 60 years, said Axsome. NMDA antagonist ...

In this study, recently published in Alzheimer's & Dementia, the authors investigated NMDA (N-methyl-D-aspartate receptors) receptors due to their importance in synaptic transmission and their ...

investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor, in Alzheimer’s disease agitation, and results of the ACCORD-2, ADVANCE-2, and long-term safety trials ...

This is when antibodies produced by the immune system attack the brain’s own proteins, in this case its NMDA receptors. This receptor is involved in learning and memory, therefore sufferers ...

N-methyl D-aspartate (NMDA) receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. Initially 5mg once daily; titrate at intervals of at least 1 week to 5mg ...